Overview

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Phase:
Phase 3
Details
Lead Sponsor:
RenovoRx
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel